BMY241213C55000
- 0.58
- -0.59-50.43%
Bristol-Myers Squibb Newsroom
Berenberg Bank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Analyst Ratings
BMO Capital Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Maintains Target Price $61
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG)
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating
Bristol-Myers Squibb Initiated at Peer Perform by Wolfe Research
Bristol-Myers Squibb Analyst Ratings
Wolfe Research Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
Daiwa Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $65
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $60 to $73
Bristol-Myers Squibb Analyst Ratings
Goldman Sachs Adjusts Bristol-Myers Squibb Price Target to $65 From $62, Maintains Buy Rating
Leerink Partners Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $73
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60